Overview

Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease

Status:
Recruiting
Trial end date:
2022-02-24
Target enrollment:
Participant gender:
Summary
The main objective of this study is to evaluate the efficacy of SZC as compared to placebo in maintaining normal sK+ in patients with hyperkalemia and metabolic acidosis associated with CKD
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca